Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 MWLDfZRwfG:6aXOgRZN{[Xl? NWjZV212OTBibl2= NG\TO2g4OiCq NGLUXFJFVVOR NHfZN3RRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> MYmyOFkxODh5Mx?=
HT-29 NGDHZlVEgXSxdH;4bYMhSXO|YYm= NEH4bHgyOCCwTR?= NWD0PGxIPzJiaB?= NF34c45FVVOR NXvBNXg4WG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NGfIVWUzPDlyMEi3Ny=>
HT-29 M{PWSGN6fG:2b4jpZ{BCe3OjeR?= NU\CO45WOTBibl2= M1HQZ|czKGh? M3vqWGROW09? M2eyO3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MlvjNlQ6ODB6N{O=
PC3 MV;LbY5ie2ViQYPzZZk> MWqxNFAhdk1? M4S4WFEhcA>? MXHEUXNQ M3PEfnBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u M2Ps[lIyQTd6Nkiz
PC3 NYn6e3ZVU2mwYYPlJGF{e2G7 NHTBWWMyODBibl2= NX7VWXhIOSCq M4TrOGROW09? MX\Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NWnCPYNLOjF7N{i2PFM>
PC3 NFTSUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0NU42KM7:TR?= MkmxNUBp MojRSG1UVw>? NI\Ib|VKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= Mlz3NlE6Pzh4OEO=
HEK293 NEPoV4RHfW6ldHnvckBCe3OjeR?= M3zVU|ExOCCwTR?= MVK4JIg> NHTYR25FVVOR MoDJTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P MmnENlE2Ozl|MEG=
BT-20 MYLLbY5ie2ViQYPzZZk> MWiyNEDPxE1? M2fNWWROW09? NE\G[IlFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= M4W4XlIyOzV|NUWx
U937 NEWzcnhCdnSrYnHjeIVzcWGuIFHzd4F6 MmnrOVAh|ryP NGLW[Hk1QCCq NUW0[|R7TE2VTx?= MY\JcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? MkC5NlEyPDJzME[=
U937 MVrBcpRq[mGldHXybYFtKEG|c3H5 M125b|UxKM7:TR?= M3;PRVQ5KGh? NW[3XVFETE2VTx?= MnjKSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MYGyNVE1OjFyNh?=
U937 MkX3RY51cWKjY4TldolidCCDc4PhfS=> MmHQOVAh|ryP MVq0PEBp NGHsWYdFVVOR NHXEcVFFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? Ml;BNlEyPDJzME[=
MCF-7 MmX6RZV1d3CqYXf5JGF{e2G7 Mm\5N|Ahdk1? MnfZOEBp MV;EUXNQ MUTJcoR2[2W|IHH1eI9xcGGpeR?= MUCyNFAzQDF|NB?=
U87MG M4OxdGtqdmG|ZTDBd5NigQ>? MknENUDPxE1? M2\OU|YhcA>? NF2xc5NFVVOR NG[wTZdRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= NUjJdIhZOTl6NEi0NFQ>
U87MG Mmn1T4lv[XOnIFHzd4F6 NFLSdoIyKM7:TR?= Mn3OOkBp NFTDZZBFVVOR M2TNcnBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MnjYNVk5PDh2MES=
U87MG NVL1XXFbU2mwYYPlJGF{e2G7 MoT0NUDPxE1? MmrFOkBp Ml;VSG1UVw>? NEPVemJFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= MUOxPVg1QDRyNB?=
U87MG NGjzRmRMcW6jc3WgRZN{[Xl? MoD3NUDPxE1? Ml;4OkBp MV7EUXNQ M2DjXmRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NEPtWFEyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb M1rNWmF2fG:yaHHnfUBCe3OjeR?= MWqwMlIh|ryP MmXLNlQhcA>? NYq0SGhoTE2VTx?= MoX0TY5lfWOnczDheZRweGijZ4m= MX[xPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 M3;BfGF2fG:yaHHnfUBCe3OjeR?= M1vJN|AvOiEQvF2= MUCyOEBp M3;nPGROW09? NWniXGJIUW6mdXPld{BifXSxcHjh[5k> M3HRNlE5OzlzOUS5
H4 NH\ZW4xHfW6ldHnvckBCe3OjeR?= NXTiRlZzOC5{IN88US=> NXfHVJZWOjRiaB?= NF3WNIxFVVOR MWnJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NUe3[m55OThyMkS1PFQ>
HeLa M{[4fmZ2dmO2aX;uJGF{e2G7 MWixNFAhdk1? MnPoN|YhcA>? MnrpSG1UVw>? M4frPGlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MXexO|U3OzN6NR?=
HeLa NX3xcmtQTnWwY4Tpc44hSXO|YYm= NFzVfooyODBibl2= MlW4N|YhcA>? NWfJdHVPTE2VTx?= MX7JcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NWHZSFVsOTd3NkOzPFU>
HeLa NXvrToRmTnWwY4Tpc44hSXO|YYm= M4Ltd|ExOCCwTR?= MWWzOkBp NXT3U2lkTE2VTx?= NH;rd4JKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NUj0cldFOTd3NkOzPFU>
SYF M{XVZ2Z2dmO2aX;uJGF{e2G7 M1iw[lExOCCwTR?= MnjRNlQhcA>? NWfGdG56TE2VTx?= MXLJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= MV6xO|U3OzN6NR?=
SYF MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNFAhdk1? M13xdlI1KGh? NUPEfppJTE2VTx?= MlT1TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MmPBNVc2PjN|OEW=
HEK293T NGPE[4xCdnSrdnnyZYwhSXO|YYm= NVHCS25kOSCwTR?= M1rwNVQh\A>? NHft[FBFVVOR M1fONGlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N NYDhcVhiOTd2OEW1NFE>
HEK293T MofPRY51cX[rcnHsJGF{e2G7 NVfZW2JyOSCwTR?= MVy0JIQ> MYnEUXNQ M4HkPGlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N NGTL[mcyPzR6NUWwNS=>
PBMC M3HscWZ2dmO2aX;uJGF{e2G7 M3rUR|Ehdk1? NFm0bFMyPCCm NGDEV|NFVVOR NWHMeWJKWmWmdXPld{BES1J3IHTlcpNqfHl? Ml;UNVc1QDV3MEG=
PBMC MUHGeY5kfGmxbjDBd5NigQ>? M1HBNFEhdk1? NEDLWFUyPCCm M2DyeWROW09? NH7Xd|ZFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? NEX6N3AyPzR6NUWwNS=>
HEK293 cells M{T0eWtqdmG|ZTDBd5NigQ>? MX61NEBvVQ>? MU[0OUBucW5? NXv5O2E{TE2VTx?= MUTJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O NX7Zb5FbOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NHfOS4RHfW6ldHnvckBCe3OjeR?= MUOxNFAhdk1? MkPROEBp MWnEUXNQ NWLC[WRyUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NHzsSngyPzF{OEK2Ni=>
Human mixed lymphocyte NV\uZZM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[xNVUhdk1? MVXEUXNQ NGqyc2RKSzVyPUGuOkBvVS5? NXnXNnZuOTZzOEW4OlU>
Lewis rat lymph node cells M{TiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jlUVUh|ryP NFXDTlNFVVOR NV;yXmdPUUN3ME2yMlYh|ryP MWqxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NULsfo56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjJNVAhdk1? M1L3N|czKGh? NYO0SoRpTE2VTx?= NYLMbm1KUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> NYDUZYVzOTByMkG5OFg>
MRK-nu-1 NGXQO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTzTWM2OD1yLki0OUBxVQ>? NYfSNnNbW0GQR1XS
OCUB-M NIe5eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGwRVNKSzVyPUWuNlQheE1? MlflV2FPT0WU
SF539 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFzLk[gdG0> MmXLV2FPT0WU
ES4 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGySG1MUUN3ME2yNU42KHCP NYX1WJh{W0GQR1XS
RL95-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3tc3RRUUN3ME2xNFcheE1? MoP1V2FPT0WU
LC-2-ad MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z0c2lEPTB;NEKzJJBO MlTkV2FPT0WU
Daudi MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTR|NDDwUS=> Mnj0V2FPT0WU
NTERA-S-cl-D1 NWf3dHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K2VmlEPTB;NESzJJBO MnfCV2FPT0WU
OS-RC-2 NUfGdo5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZ3MjDwUS=> M4f1XHNCVkeHUh?=
VA-ES-BJ NXjKeXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS2V3BKSzVyPUeyN{BxVQ>? MWDTRW5ITVJ?
GR-ST MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7peJRkUUN3ME24OFYheE1? NHnHV5NUSU6JRWK=
SW872 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLHUVdnUUN3ME24OFYheE1? MV\TRW5ITVJ?
NOS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjaTWM2OD16N{GgdG0> NVTQUHN2W0GQR1XS
MC116 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLsR3VKSzVyPUm4OUBxVQ>? M2j4e3NCVkeHUh?=
NCI-H1355 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rl[WlEPTB;MT6wNUBvVQ>? MknyV2FPT0WU
RPMI-8226 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMUmgcm0> MlPvV2FPT0WU
TE-15 NHmzO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q4T2lEPTB;MT6zOkBvVQ>? MoXjV2FPT0WU
Ramos-2G6-4C10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf4S4FYUUN3ME2xMlQ3KG6P Ml7FV2FPT0WU
KU812 M1H5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwMEGgcm0> M2DKOnNCVkeHUh?=
EW-1 NVWwbId5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDWTWM2OD1{LkG3JI5O M4rXd3NCVkeHUh?=
KS-1 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNEWgcm0> MlXNV2FPT0WU
SK-LMS-1 NGfn[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHFTWM2OD1{LkS5JI5O NXLX[mJ1W0GQR1XS
TGBC1TKB NXXpV2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Tc2lEPTB;Mj62PUBvVQ>? NVXEO2x7W0GQR1XS
TE-6 NWnmboVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDZVpBKSzVyPUKuO|chdk1? M{fqWXNCVkeHUh?=
ETK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln5TWM2OD1{LkiyJI5O M3L2XXNCVkeHUh?=
BE-13 NUmyRnBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LsW2lEPTB;Mj65PUBvVQ>? MWjTRW5ITVJ?
A3-KAW NFrSR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGXIxKSzVyPUKuPVkhdk1? MnTjV2FPT0WU
TE-10 MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPKRndKSzVyPUOuN{BvVQ>? Ml64V2FPT0WU
DOHH-2 NW\uc3Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TOWWlEPTB;Mz6zOUBvVQ>? M1q2PXNCVkeHUh?=
ES6 M1e4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwNEOgcm0> M32yWnNCVkeHUh?=
OPM-2 NV:yNGVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTRwMUWgcm0> MUHTRW5ITVJ?
SH-4 NWq1S4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzJW3VKSzVyPUSuN|Qhdk1? M3zTRXNCVkeHUh?=
NB13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofWTWM2OD12LkO2JI5O M374e3NCVkeHUh?=
HUTU-80 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwNEKgcm0> Mn\jV2FPT0WU
CCRF-CEM NFuwN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Qd|VKSzVyPUSuPVQhdk1? MULTRW5ITVJ?
TGBC24TKB M{TZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n1XmlEPTB;NT61NUBvVQ>? NHzZVZhUSU6JRWK=
697 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnhUGZ6UUN3ME22MlI5KG6P MV7TRW5ITVJ?
J-RT3-T3-5 NYr1TXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTv[3RKSzVyPU[uOFYhdk1? Mm\oV2FPT0WU
KALS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Wb5oxUUN3ME22MlU3KG6P MX\TRW5ITVJ?
no-10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTdwMkmgcm0> M2\RNnNCVkeHUh?=
SK-NEP-1 M3vwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHXVIY{UUN3ME24Mlc6KG6P NIfJWlBUSU6JRWK=
L-540 M4LiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTmU5BZUUN3ME2xNE41OiCwTR?= MYjTRW5ITVJ?
JiyoyeP-2003 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HBcGlEPTB;MUCuPVQhdk1? MVjTRW5ITVJ?
HH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzyTWM2OD1zMT6zPUBvVQ>? M{DUVHNCVkeHUh?=
SR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:xTWM2OD1zMT60OUBvVQ>? MUPTRW5ITVJ?
QIMR-WIL M1y4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;CfWlEPTB;MUGuPFUhdk1? MV;TRW5ITVJ?
A4-Fuk NX3XdnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[5NGlEPTB;MUOuNVIhdk1? M1K0bnNCVkeHUh?=
CESS NXHvO29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjKbFNKSzVyPUGzMlE{KG6P NFXlSJJUSU6JRWK=
KE-37 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF4LkC3JI5O NWH4U|RGW0GQR1XS
SK-UT-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq3RpM3UUN3ME2xOk45OSCwTR?= NV7RTIF[W0GQR1XS
SIG-M5 NGnIVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jJbGlEPTB;MUeuNlUhdk1? M4rHTHNCVkeHUh?=
HT MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;ETWM2OD1zNz62JI5O MXXTRW5ITVJ?
DEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\CRlZwUUN3ME2xO{46QSCwTR?= NUmyRpl7W0GQR1XS
SK-PN-DW MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTvTWM2OD1{MD6yN{BvVQ>? MW\TRW5ITVJ?
RPMI-8402 NYC4UIxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonoTWM2OD1{MT63O{BvVQ>? NWSyOGtCW0GQR1XS
RPMI-6666 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXkTWM2OD1{ND60NkBvVQ>? NFH0fYdUSU6JRWK=
NCI-H720 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLQTWM2OD1{NT60NUBvVQ>? NWK1XHBUW0GQR1XS
EW-16 MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPzeFZKSzVyPUK2Mlg4KG6P MWPTRW5ITVJ?
BL-70 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ6LkO4JI5O NH\wRmRUSU6JRWK=
SF126 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnjSYVyUUN3ME2zNE4{QCCwTR?= NUnGRmNGW0GQR1XS
BC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnwfZRKSzVyPUOxMlI3KG6P NF;Pb2hUSU6JRWK=
MHH-PREB-1 NUXqZ5dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLKbHJKSzVyPUOyMlQ1KG6P MWTTRW5ITVJ?
A101D MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD6TWM2OD1|Mj62NkBvVQ>? MnnzV2FPT0WU
NMC-G1 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN|Lk[3JI5O MYHTRW5ITVJ?
LB1047-RCC NHnQ[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHjTHI{UUN3ME2zOE43QSCwTR?= NFzFZW1USU6JRWK=
EM-2 NIK3fGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHjTWM2OD1|OD61N{BvVQ>? M3P1RXNCVkeHUh?=
COLO-684 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN7Lkigcm0> MmjOV2FPT0WU
Becker M4K2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRzLkC1JI5O M{fBS3NCVkeHUh?=
BL-41 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXGTWM2OD12Mz62OkBvVQ>? NELkVlZUSU6JRWK=
MDA-MB-134-VI MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nUVmlEPTB;NESuNFIhdk1? MXXTRW5ITVJ?
L-363 NX3DOZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvJW|RxUUN3ME20OE44OyCwTR?= M4T5PXNCVkeHUh?=
ECC4 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ftVGlEPTB;NESuO|ghdk1? MnzFV2FPT0WU
A388 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR2LkiyJI5O MXTTRW5ITVJ?
HEL NEKzXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj0UZVKSzVyPUS5Mlc6KG6P MlTMV2FPT0WU
RKO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTPR|lKSzVyPUWwMlI6KG6P NYfuVXdZW0GQR1XS
KINGS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrqSFFKSzVyPUWxMlU2KG6P MWjTRW5ITVJ?
EB-3 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSwSocxUUN3ME21Nk43PyCwTR?= MUDTRW5ITVJ?
ARH-77 NH[xZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PwWGlEPTB;NUKuPEBvVQ>? NWnDTYlHW0GQR1XS
GCIY M3TNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD13Mz60OkBvVQ>? NYqxbXk3W0GQR1XS
NCI-H1304 NW\wZY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG4TWM2OD13Nz6yNkBvVQ>? M{LUcHNCVkeHUh?=
KARPAS-299 NY[yZYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnWSlRKSzVyPU[xMlgzKG6P MkiyV2FPT0WU
IA-LM NUfHSI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZ6LkGzJI5O MVrTRW5ITVJ?
GI-1 NXjtRZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTdyLkO5JI5O M3Pa[3NCVkeHUh?=
TE-11 M3f2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DscGlEPTB;N{euNVchdk1? NEjIfWhUSU6JRWK=
LS-411N MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDNSIw4UUN3ME23O{42PyCwTR?= M3nTeHNCVkeHUh?=
no-11 M13qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTh|LkK0JI5O MnLyV2FPT0WU
MV-4-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLTTWM2OD16Mz63N{BvVQ>? M3TRcXNCVkeHUh?=
BV-173 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1U2lEPTB;OEOuPVchdk1? MYrTRW5ITVJ?
CMK MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrPRW1lUUN3ME24OE4yPiCwTR?= M1nr[3NCVkeHUh?=
LC4-1 M{HsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT5TWM2OD16Nj63NkBvVQ>? NEj6fFVUSU6JRWK=
COR-L279 M162bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTh5LkK1JI5O MYjTRW5ITVJ?
NCI-H209 NUOxZXFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\4NVZyUUN3ME24O{41OSCwTR?= NYr5TFNtW0GQR1XS
Raji NEKxcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTh7LkeyJI5O Mn74V2FPT0WU
LB996-RCC NF\TVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTl|LkSzJI5O NXLidZE1W0GQR1XS
NCI-H526 NHTFUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH0eIdKSzVyPUmzMlU6KG6P MUPTRW5ITVJ?
KGN NX\EcZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCwSpZHUUN3ME25Ok4zQSCwTR?= MXnTRW5ITVJ?
MOLT-4 NWTMNYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfGWFM3UUN3ME25Ok44QSCwTR?= NIrFW4FUSU6JRWK=
PF-382 M2PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nJW2lEPTB;OU[uO|khdk1? MVLTRW5ITVJ?
BC-3 NFvOS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTjTWM2OD17OT6xPEBvVQ>? M1jqO3NCVkeHUh?=
KARPAS-422 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fj[WlEPTB;MUCyMlA6KG6P M4nEO3NCVkeHUh?=
SBC-1 NILMNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGewZo5KSzVyPUGwO{44PSCwTR?= NEDtV5RUSU6JRWK=
LC-1F NXnHRZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnjdlJKSzVyPUGwPE4xPSCwTR?= MmfMV2FPT0WU
GB-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HsN2lEPTB;MUC5MlAzKG6P NYTrOoJJW0GQR1XS
SNB75 M2TJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFzOT62PUBvVQ>? NFfFVJpUSU6JRWK=
BB65-RCC NVzUT|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz5SoVKSzVyPUGxPU46OyCwTR?= NET3Zo5USU6JRWK=
NCI-N87 M3XIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF{MT65PEBvVQ>? M1;3VnNCVkeHUh?=
IST-MEL1 M3jDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\o[45VUUN3ME2xNlIvOzhibl2= MXfTRW5ITVJ?
HOP-62 M2PNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L2R2lEPTB;MUK2Mlg6KG6P MXHTRW5ITVJ?
ACN NWfOfpZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f6R2lEPTB;MUS2Mlc2KG6P NXu1bXFjW0GQR1XS
DMS-114 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH5THZMUUN3ME2xOVAvPjdibl2= NVr1eXJKW0GQR1XS
MLMA NYfRW2l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF3OT64PEBvVQ>? NF7KOIxUSU6JRWK=
HT-144 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnJTWM2OD1zNkWuOFMhdk1? NX7pXXhnW0GQR1XS
C2BBe1 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTVTYdyUUN3ME2xOlcvPzZibl2= MlLpV2FPT0WU
L-428 M1ezOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF5Nz63JI5O NUjLR29qW0GQR1XS
DU-4475 NVTQNWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrRbmUzUUN3ME2xPFcvPjhibl2= NFPHU3NUSU6JRWK=
CP67-MEL NFHJcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvP[VVKSzVyPUG5PU4{QCCwTR?= MlToV2FPT0WU
MEG-01 NV7sdZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJyMT65OkBvVQ>? NFXFZ2NUSU6JRWK=
IST-SL2 NF\5NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJyOD62N{BvVQ>? MYXTRW5ITVJ?
ES8 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3XHJKSzVyPUKyOU46PCCwTR?= Mn3OV2FPT0WU
COLO-800 M3HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[3XGlEPTB;MkO1MlI5KG6P NVfJOFh5W0GQR1XS
MFH-ino NFXqR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rVVWlEPTB;MkO1Mlg1KG6P NYTVVWFIW0GQR1XS
OVCAR-4 NV[1XII3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TFRWlEPTB;MkO3MlI1KG6P NXzrUGNEW0GQR1XS
PSN1 NVTMTmRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXvTWM2OD1{NEKuO|Ehdk1? M2XvUHNCVkeHUh?=
EW-12 NGS1NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJ2Mz6xJI5O M3rOWnNCVkeHUh?=
HCC1599 M2TrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDCeIhKSzVyPUK2NU41PyCwTR?= NV6zPIZ6W0GQR1XS
SJSA-1 M3Htdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL6cIxKSzVyPUK3NU41PiCwTR?= M3GyXnNCVkeHUh?=
ST486 M3LBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jmbWlEPTB;Mkm2MlE1KG6P MUTTRW5ITVJ?
NOMO-1 M3LobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\IdmlEPTB;M{CwMlIyKG6P MXPTRW5ITVJ?
MN-60 NEDuSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPsTWM2OD1|MEWuN|Ihdk1? NIf6XZVUSU6JRWK=
HCC1187 NVfBZoExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;ETWM2OD1|MEeuNlUhdk1? MojhV2FPT0WU
SW982 NV;TS5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37lOGlEPTB;M{G0Mlc2KG6P M331N3NCVkeHUh?=
LB647-SCLC NXfUdY15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nTSGlEPTB;M{K4MlcyKG6P NEexUo1USU6JRWK=
HC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrubYt7UUN3ME2zN|UvPSCwTR?= NXHVOIo2W0GQR1XS
EHEB NGr6NWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTN|Nz61NkBvVQ>? Mk\MV2FPT0WU
TUR MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;rcJBKSzVyPUO2N{46PSCwTR?= NH[yUHhUSU6JRWK=
LU-139 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm2VHF3UUN3ME2zO|gvODJibl2= M3f1TnNCVkeHUh?=
NB1 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN6ND60OUBvVQ>? MnHLV2FPT0WU
BB30-HNC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfMVVJLUUN3ME2zPFgvOzJibl2= NUHpOIlpW0GQR1XS
HAL-01 NXzt[G8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\QV2dKSzVyPUO4PU4zPiCwTR?= Mn\lV2FPT0WU
K5 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:wSGlEPTB;NEGxMlM4KG6P M4PKUHNCVkeHUh?=
MZ2-MEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX4TWM2OD12MUOuOlQhdk1? M4L6UnNCVkeHUh?=
RXF393 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjl[2JKSzVyPUSxOk41PSCwTR?= MkDVV2FPT0WU
NCI-H1648 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRzNz61N{BvVQ>? MkG2V2FPT0WU
TE-12 NWDvRoRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPDW2s{UUN3ME20N|QvOjZibl2= MUHTRW5ITVJ?
EoL-1- MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fS[WlEPTB;NEO3Mlk5KG6P NWnRdHFtW0GQR1XS
JAR NGHIXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TsPWlEPTB;NEO4MlYzKG6P M{PhXnNCVkeHUh?=
DSH1 M2jWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX2TWM2OD12NUiuPVEhdk1? NUDYclk1W0GQR1XS
NCI-H187 NFvBT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe2XZRnUUN3ME20OlIvQDFibl2= NH7YO2ZUSU6JRWK=
HCE-4 NUiwV481T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K3U2lEPTB;NEe3MlY3KG6P M2nKfHNCVkeHUh?=
8-MG-BA NUjtdYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[2R3F4UUN3ME21PFEvPTJibl2= MnnyV2FPT0WU
KLE M3nn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\teYljUUN3ME21PFUvOiCwTR?= NYLt[mo5W0GQR1XS
KNS-42 M165Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T0dmlEPTB;NUi2MlgyKG6P NW\0PYFIW0GQR1XS
MSTO-211H NWiwZ2tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq0b|ZKSzVyPU[wPU44PCCwTR?= NXL5THNFW0GQR1XS
GDM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZzND6wPUBvVQ>? M1LpUXNCVkeHUh?=
TE-1 M3LGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\qN2lEPTB;NkS2MlEzKG6P NUXTPWFbW0GQR1XS
BT-474 NFTIdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T4NmlEPTB;NkS3MlA3KG6P MofiV2FPT0WU
KARPAS-45 NFTQbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzoZpJ7UUN3ME22OFcvPiCwTR?= MlHnV2FPT0WU
MOLT-16 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXCTWM2OD14NEeuPVMhdk1? NEC5[HVUSU6JRWK=
KURAMOCHI NX3peVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPZTWM2OD14NUeuOVEhdk1? M2HmPHNCVkeHUh?=
K-562 M2q0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj2V21KSzVyPU[2PU42OSCwTR?= MnPjV2FPT0WU
EKVX MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZ5Mj63NUBvVQ>? Mn7XV2FPT0WU
GAK M1jVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m1c2lEPTB;Nke1MlMhdk1? MorxV2FPT0WU
NCI-SNU-5 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTZ7MD6wNUBvVQ>? NHm4U|NUSU6JRWK=
NCI-H2126 NWjqWI4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLUXXRKSzVyPUeyOk45PyCwTR?= NEXiS21USU6JRWK=
CTV-1 NWr3ZYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqcWJ{UUN3ME23OFQvQSCwTR?= M1yyRnNCVkeHUh?=
SW962 NVHF[nh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD15NEiuOFQhdk1? NF7XcJlUSU6JRWK=
MONO-MAC-6 M4nlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2N|VKSzVyPUe1Ok46OyCwTR?= M4e3cnNCVkeHUh?=
NCI-H748 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTd3OD65PUBvVQ>? NVrRUWFKW0GQR1XS
NCI-H524 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnWTINOUUN3ME23PFAvPzNibl2= M4LhRXNCVkeHUh?=
LS-123 NVG5TnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHhblJKSzVyPUe5OU43QSCwTR?= NHrqNYpUSU6JRWK=
NB7 NH7KZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33KUGlEPTB;OEG0MlE1KG6P MYnTRW5ITVJ?
LS-1034 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTTcXJKSzVyPUiyPE46QCCwTR?= MkLLV2FPT0WU
TE-5 M3LJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTh6Mz61OkBvVQ>? MVnTRW5ITVJ?
A704 M1r3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILsT4FKSzVyPUi5PU4yPSCwTR?= M1zDRXNCVkeHUh?=
TK10 M1i5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrkTWM2OD17MU[uNFMhdk1? NFHzcGNUSU6JRWK=
NCI-H345 M4HU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TmVGlEPTB;OUSzMlIzKG6P M2LYOHNCVkeHUh?=
CGTH-W-1 NI\ofmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLQTWM2OD17NEiuNVMhdk1? M2HGOXNCVkeHUh?=
NCI-H510A MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjlenZKSzVyPUm4OU4yOiCwTR?= NHrWdZdUSU6JRWK=
NCI-H1963 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKySXRGUUN3ME2xMlA{Ojl{IN88US=> NEHySVhUSU6JRWK=
SCC-3 M3[zRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\oV2lEPTB;MT6wN|QyPCEQvF2= NYjkeZJKW0GQR1XS
EW-11 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\GTWM2OD1zLkC4O|Q{KM7:TR?= NX;t[ZZSW0GQR1XS
CPC-N M13ScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2yTWM2OD1zLkC4PEDPxE1? NEHPS3lUSU6JRWK=
NCI-H1417 M{XFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFwMUKyOkDPxE1? MWLTRW5ITVJ?
DG-75 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PBN2lEPTB;MT6xOlI5PSEQvF2= M2PZfnNCVkeHUh?=
HD-MY-Z MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:xWYN4UUN3ME2xMlE3PDF4IN88US=> M13GcnNCVkeHUh?=
ATN-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r0WGlEPTB;MT6yOlIxQSEQvF2= NH7lPWlUSU6JRWK=
KM-H2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f0VWlEPTB;MT6yOlQxQCEQvF2= MWrTRW5ITVJ?
NCI-H2081 NF[3fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXpTWM2OD1zLkK2OlM4KM7:TR?= MYfTRW5ITVJ?
HL-60 NY\mVYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HPS2lEPTB;MT6yOlk2QSEQvF2= MYDTRW5ITVJ?
DB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHRNYJrUUN3ME2xMlI4OjR{IN88US=> MYfTRW5ITVJ?
NCI-H1522 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfpTWM2OD1zLkK4PFg4KM7:TR?= NX\JZ4xEW0GQR1XS
AM-38 NVjV[mVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:z[nNyUUN3ME2xMlMxPzJizszN NEjLXpdUSU6JRWK=
NCI-H446 M{jSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGwTWM2OD1zLkOyNVIyKM7:TR?= M{G1T3NCVkeHUh?=
SU-DHL-1 NIG2e4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7zTo5JUUN3ME2xMlMzQDBzIN88US=> MnLiV2FPT0WU
NH-12 M1jaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3VTGhKSzVyPUGuN|Y{PzRizszN NGHWOWtUSU6JRWK=
DMS-79 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M136WmlEPTB;MT6zOlg3PiEQvF2= NF3U[ZdUSU6JRWK=
NCI-H716 NYfoTGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvQTWM2OD1zLkO4PVg3KM7:TR?= NH6zWWhUSU6JRWK=
ML-2 NWS5S4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v6UWlEPTB;MT60NVUzQSEQvF2= MnrKV2FPT0WU
NB10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H4SmlEPTB;MT60OlY{OiEQvF2= NX\YZotxW0GQR1XS
ONS-76 NIj5ZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmze5pKSzVyPUGuOVM2PjlizszN M1G3OHNCVkeHUh?=
LOUCY MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i3ZmlEPTB;MT61OFY2PyEQvF2= NX3SbmN3W0GQR1XS
SCLC-21H MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTOV|VKSzVyPUGuOVg2QDJizszN MmjwV2FPT0WU
TGW MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq4TWM2OD1zLk[zPVc2KM7:TR?= NHTxTVBUSU6JRWK=
LXF-289 NX7E[mlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD1zLkezNlY5KM7:TR?= NEHl[|FUSU6JRWK=
BB49-HNC Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLHTWM2OD1zLkezOVg3KM7:TR?= M{HXeHNCVkeHUh?=
NCI-H747 NWPyRZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDZWlEPTB;MT63OVM1PiEQvF2= MWHTRW5ITVJ?
LU-165 NYWzTJQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwOES5PFYh|ryP MUfTRW5ITVJ?
OMC-1 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPPSY5KSzVyPUGuPVUxPjZizszN M1TMfXNCVkeHUh?=
RCC10RGB NYPWO3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1UpZzUUN3ME2xMlk2QDF5IN88US=> M4C1eHNCVkeHUh?=
SW684 M3ywbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITSXnhKSzVyPUGuPVYxQTlizszN NIDmZ4tUSU6JRWK=
TE-8 M2fQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzHPJlRUUN3ME2yMlA2PTV7IN88US=> M4XmWHNCVkeHUh?=
SK-N-DZ NVvBfmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r1S2lEPTB;Mj6xN|I4PCEQvF2= M4rpcnNCVkeHUh?=
EVSA-T NH;yZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfVcIdrUUN3ME2yMlE4OzF3IN88US=> NGi1[nVUSU6JRWK=
KASUMI-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwMUi4NVUh|ryP NEjxfGRUSU6JRWK=
NKM-1 NIDWbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHlN|Z[UUN3ME2yMlI2PDd{IN88US=> NHzHXFNUSU6JRWK=
CAL-148 NEOyUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXfJZKSzVyPUKuN|M3OTRizszN MnjMV2FPT0WU
NCI-H64 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrlTWM2OD1{LkO0NlMzKM7:TR?= MYnTRW5ITVJ?
KNS-81-FD NGXmcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS2bXJtUUN3ME2yMlM3PjJizszN M{TMTnNCVkeHUh?=
KM12 NH;6[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L2RmlEPTB;Mj60NFg{QSEQvF2= NUXoWpBlW0GQR1XS
SW954 M3fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq0OYgyUUN3ME2yMlQ4Pzd7IN88US=> NH7ZR4xUSU6JRWK=
NCI-H1395 NYrpXHRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDsTWM2OD1{LkWyOlQ2KM7:TR?= M1fPT3NCVkeHUh?=
DJM-1 M{DsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnr[|BKSzVyPUKuOlA3OyEQvF2= MXPTRW5ITVJ?
COLO-668 NV60T5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLRTWM2OD1{LkiyOlk2KM7:TR?= MWPTRW5ITVJ?
NCI-H1436 M2KxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTUeFJKSzVyPUKuPFU3OTVizszN M2P6NnNCVkeHUh?=
LB2241-RCC M1fBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvUTWM2OD1{Lki2PFM6KM7:TR?= MmfyV2FPT0WU
GT3TKB NF\QZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjrV5hKSzVyPUKuPFkxPTVizszN NECydItUSU6JRWK=
COLO-824 M4[4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jHWWlEPTB;Mj64PVc3QCEQvF2= NXT0flN3W0GQR1XS
ES1 NWLWbWdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zjTWlEPTB;Mj64PVg4QSEQvF2= NU\nOXl{W0GQR1XS
LB771-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37uWWlEPTB;Mj65NFk1PiEQvF2= MmTjV2FPT0WU
GI-ME-N M{HpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD1TWM2OD1|LkCwPVA1KM7:TR?= MWHTRW5ITVJ?
NALM-6 M4jRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwMEC5N|Mh|ryP MmrPV2FPT0WU
LU-134-A NUTkV454T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rxTWlEPTB;Mz6wOVQzPSEQvF2= M3rWcHNCVkeHUh?=
DMS-153 NF7lS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP0[3lZUUN3ME2zMlA2QDJ2IN88US=> MY\TRW5ITVJ?
MZ1-PC M4fj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPYTWM2OD1|LkC5NFc5KM7:TR?= MmPtV2FPT0WU
NCI-H1155 M3nnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S0fmlEPTB;Mz6xNVYyKM7:TR?= M4rDR3NCVkeHUh?=
CAS-1 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwMUO3NFch|ryP M1TDdHNCVkeHUh?=
D-502MG NGrQdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwMUSzPUDPxE1? MWHTRW5ITVJ?
NCI-H2141 NWDpOGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV31dI9GUUN3ME2zMlE4PDV{IN88US=> MWXTRW5ITVJ?
NB6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwMUiyOVkh|ryP M1excHNCVkeHUh?=
NCCIT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwMkG4NFkh|ryP MXHTRW5ITVJ?
NB69 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTNwM{G4PVEh|ryP MX;TRW5ITVJ?
JVM-2 M4TxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoXJFKSzVyPUOuN|Y1OzNizszN MVvTRW5ITVJ?
K052 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6cXZyUUN3ME2zMlM4QTZ6IN88US=> NHfUPZBUSU6JRWK=
HCC2157 NGXqO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwNUOyNlgh|ryP NFL4bWdUSU6JRWK=
KMOE-2 NF6zc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwNUSyOFIh|ryP MnjZV2FPT0WU
SF268 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwN{G1OVQh|ryP NUK4WotkW0GQR1XS
CHP-126 NX;4eWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LhZWlEPTB;Mz63OlQ2QCEQvF2= NG\NVXhUSU6JRWK=
CP66-MEL NWe5RolKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[4Z|JKSzVyPUOuO|kxQTRizszN Ml;GV2FPT0WU
NCI-H69 M{nBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\zd3BKSzVyPUSuNFE6OzZizszN MVnTRW5ITVJ?
A253 NE\UdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf5PGlKSzVyPUSuNFIyODFizszN MlviV2FPT0WU
NB14 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jRS2lEPTB;ND6xNFQ4QSEQvF2= MX7TRW5ITVJ?
NCI-H1694 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\pV|FXUUN3ME20MlE{OTF{IN88US=> NH3m[VVUSU6JRWK=
NCI-H2196 NFq1VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zOUmlEPTB;ND6xO|E3QSEQvF2= NHzINmVUSU6JRWK=
TE-9 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRwMUe1PFIh|ryP MkLDV2FPT0WU
D-283MED MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwMUi4OEDPxE1? NVzKU|BnW0GQR1XS
OCI-AML2 NGi3enpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDsTWM2OD12LkG5OFg6KM7:TR?= M3vYeXNCVkeHUh?=
D-263MG NIW3Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle1TWM2OD12LkKyPVYyKM7:TR?= NV\5UWw6W0GQR1XS
MPP-89 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTLbZdLUUN3ME20MlI4OzB2IN88US=> M1e2[HNCVkeHUh?=
LAMA-84 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u3NmlEPTB;ND6zNFQzOSEQvF2= MXnTRW5ITVJ?
LB373-MEL-D M1jRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTRwM{[3PFkh|ryP Ml\CV2FPT0WU
UACC-257 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzlTWM2OD12LkO5OVM1KM7:TR?= NUHBXmhoW0GQR1XS
MC-CAR M2TpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rPNWlEPTB;ND60N|k6KM7:TR?= NFvSOIFUSU6JRWK=
COLO-320-HSR NEHlfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzPOIdZUUN3ME20MlQ1PDJ5IN88US=> M1rNUXNCVkeHUh?=
P30-OHK MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwNk[1PFEh|ryP NWjsNVl2W0GQR1XS
UACC-812 M3fi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi1TWM2OD12Lk[5NVYyKM7:TR?= M3m5S3NCVkeHUh?=
CTB-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PobWlEPTB;ND63NVU2PSEQvF2= M{LHenNCVkeHUh?=
ALL-PO MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK3OItXUUN3ME20Mlg1ODd5IN88US=> MUfTRW5ITVJ?
SK-MEL-2 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;i[HRKSzVyPUSuPFY6PTVizszN NFrRV4hUSU6JRWK=
TC-YIK M{K1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vEVGlEPTB;ND65O|k1OiEQvF2= MY\TRW5ITVJ?
NCI-H1882 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTVwMEKwNFEh|ryP NITUenRUSU6JRWK=
MHH-CALL-2 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX25dJEyUUN3ME21MlA2ODR{IN88US=> NFHDOlJUSU6JRWK=
U-87-MG NX:0ZoZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTVwMEm0OlYh|ryP MWDTRW5ITVJ?
NCI-H1092 NV31T2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXqTWM2OD13LkK2OVU2KM7:TR?= M2XJT3NCVkeHUh?=
TE-441-T NGX1bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH5flRKSzVyPUWuNlc5OiEQvF2= MVTTRW5ITVJ?
SK-MEL-1 NFnaOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjqS2lKSzVyPUWuNlkxPDRizszN NGr2VoFUSU6JRWK=
EW-22 NETZOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW1TWM2OD13LkK5OFY3KM7:TR?= NIjwW|dUSU6JRWK=
MZ7-mel M3rQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnwXIUxUUN3ME21MlQxPjlzIN88US=> M4nuc3NCVkeHUh?=
LP-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnFV2l3UUN3ME21MlQyOjlzIN88US=> Mm\xV2FPT0WU
NCI-SNU-16 NGLHS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTVwNkSwO|Qh|ryP NFLq[FJUSU6JRWK=
LU-65 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5TWM2OD13Lke2N|c{KM7:TR?= NFXsW4FUSU6JRWK=
CW-2 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[5Xno1UUN3ME21Mlg2QTV7IN88US=> MnzaV2FPT0WU
WSU-NHL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPlTWM2OD13Lkm1NVc1KM7:TR?= NF;JdW5USU6JRWK=
IST-MES1 NEniTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPlT25KSzVyPUWuPVU1PDNizszN NULMc2pNW0GQR1XS
U-266 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTVwOUiyNFIh|ryP NF7iNo1USU6JRWK=
TALL-1 M13NbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm0cJFWUUN3ME22MlE1Pjh6IN88US=> NEC1T49USU6JRWK=
Calu-6 M2TpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf2TWM2OD14LkG1N|E3KM7:TR?= M1;qWHNCVkeHUh?=
MMAC-SF M360Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\1TWM2OD14LkG4OVU3KM7:TR?= NF;D[ZhUSU6JRWK=
NCI-H82 NHPoU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvpTWM2OD14LkKwOFg6KM7:TR?= M1vGdHNCVkeHUh?=
RS4-11 M4G2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZwMkW4PVch|ryP M3\vTHNCVkeHUh?=
SNU-C2B M4DOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL2TWM2OD14LkSwPVY6KM7:TR?= Mk[yV2FPT0WU
BOKU NYKyNZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXzbnJrUUN3ME22MlQ4PTl5IN88US=> NITX[3NUSU6JRWK=
C8166 NVvwNYNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnnTWM2OD14LkW1PVEzKM7:TR?= NWLjN|lCW0GQR1XS
D-247MG NHfLZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4myR2lEPTB;Nz6wOFM1PyEQvF2= MUjTRW5ITVJ?
EW-18 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ez[mlEPTB;Nz6wO|I6OiEQvF2= MWXTRW5ITVJ?
KG-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD15Lk[yO|M5KM7:TR?= NWXHcpN4W0GQR1XS
REH M33meGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD15Lk[4NVA6KM7:TR?= MUnTRW5ITVJ?
U-698-M MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PYS2lEPTB;Nz64OFMyPSEQvF2= MXvTRW5ITVJ?
KP-N-RT-BM-1 M1;tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlznTWM2OD15LkmzNFI6KM7:TR?= M{DhVXNCVkeHUh?=
MS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XtOGlEPTB;Nz65OlA1OSEQvF2= NIr4bppUSU6JRWK=
SNU-C1 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mxNWlEPTB;Nz65PFE6OiEQvF2= NX;ZWFRCW0GQR1XS
SK-MM-2 NXPhO3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\wdHBMUUN3ME24MlI3ODZ3IN88US=> NF74fHdUSU6JRWK=
LAN-6 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLuTWM2OD16LkOwNFAyKM7:TR?= MlXZV2FPT0WU
NEC8 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwM{C2PVEh|ryP M3rwR3NCVkeHUh?=
NCI-H1770 M3fQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW4NlM2UUN3ME24MlM5ODB{IN88US=> NWn4Nm9DW0GQR1XS
D-336MG MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRThwNECxNVYh|ryP MX\TRW5ITVJ?
COLO-829 M4q0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3FTWM2OD16LkS4PFc6KM7:TR?= MmnCV2FPT0WU
LS-513 NGLk[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTxWlhKSzVyPUiuOVk2QTlizszN NF64O|ZUSU6JRWK=
YT NEnj[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\3[mlEPTB;OD62NlQzPyEQvF2= MmTpV2FPT0WU
EW-24 NGjJdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ZT5BKSzVyPUiuO|Y2PCEQvF2= MnXYV2FPT0WU
IST-SL1 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPucIxKSzVyPUiuPFY2PDNizszN NYDRSHA4W0GQR1XS
CA46 M1yzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK4TWM2OD16Lkm1NFk5KM7:TR?= NY\kc3lsW0GQR1XS
NCI-H1838 M4\aemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvCcVhRUUN3ME24Mlk5PjB{IN88US=> NHrvbFhUSU6JRWK=
NCI-H719 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES0NGdKSzVyPUmuNlUzPzlizszN M1\Nb3NCVkeHUh?=
HCE-T NE\zTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\6TmlEPTB;OT6zNFg2OSEQvF2= MmTXV2FPT0WU
A498 NGjlb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwM{[xNlQh|ryP NXy4fY1TW0GQR1XS
LB831-BLC NH:5VYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e1dGlEPTB;OT63OlUzOSEQvF2= MVnTRW5ITVJ?
SKM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOybGZjUUN3ME25Mlg2QTZ|IN88US=> NV74ZnBqW0GQR1XS
THP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETZPFRKSzVyPUmuPVY6OThizszN MoTBV2FPT0WU
SHP-77 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFyLkSwO{DPxE1? M3rHTnNCVkeHUh?=
EW-3 M3zaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHlTWM2OD1zMD62Nlg6KM7:TR?= MoDlV2FPT0WU
KY821 NFPLU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTBOpU1UUN3ME2xNE44PjNizszN MVXTRW5ITVJ?
NCI-SNU-1 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFzLkCyNVch|ryP MofvV2FPT0WU
HCC2218 M4PLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;mSmlEPTB;MUGuN|k5PiEQvF2= MmnnV2FPT0WU
IM-9 M{XXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFzLkWxNFYh|ryP M{\LdXNCVkeHUh?=
NCI-H889 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfaUZF6UUN3ME2xNU42OzF|IN88US=> M1vnb3NCVkeHUh?=
HDLM-2 M2PUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{LkSxOVkh|ryP NWjaWGR{W0GQR1XS
LB2518-MEL MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PhOWlEPTB;MUKuOlgyPSEQvF2= NWnxXmxyW0GQR1XS
NCI-H23 NIDNdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fGSGlEPTB;MUOuNlQzPSEQvF2= MoLUV2FPT0WU
NB17 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF|LkS1O|kh|ryP MkLzV2FPT0WU
NCI-H322M MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnGTWM2OD1zND60NFY5KM7:TR?= M1jqVHNCVkeHUh?=
SUP-T1 M{Pvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jn[2lEPTB;MUSuOFE{KM7:TR?= NVHFTWZIW0GQR1XS
ES3 M4iwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF3LkC3NFMh|ryP M4HiW3NCVkeHUh?=
ES5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j1fmlEPTB;MUWuNFc5PyEQvF2= MoLkV2FPT0WU
NCI-H1650 M4HSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DLVWlEPTB;MUWuOFk4QSEQvF2= Mm\kV2FPT0WU
NCI-H226 M4D6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[3fpBKSzVyPUG1Mlg4PjhizszN NYDDUXVjW0GQR1XS
COR-L88 M2flcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGzcolKSzVyPUG2MlMyPCEQvF2= MVfTRW5ITVJ?
SCC-15 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF4LkO4Olkh|ryP NXXC[Hh{W0GQR1XS
GOTO NFXjSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrGeGc3UUN3ME2xOk41Pzl|IN88US=> M3HUSnNCVkeHUh?=
SIMA NUH4UIRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fLeWlEPTB;MU[uOFgxOiEQvF2= NXPifJdtW0GQR1XS
NCI-H1299 NFHpVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TscmlEPTB;MUeuNVU6OSEQvF2= MVPTRW5ITVJ?
NCI-H1581 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;Ld2lEPTB;MUeuOFIyQSEQvF2= NWfaN5A4W0GQR1XS
MHH-NB-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF5Lkm2PFMh|ryP M4G2RXNCVkeHUh?=
MFM-223 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF6LkC1N|gh|ryP MkjMV2FPT0WU
ES7 NInWdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF6LkW0N|Eh|ryP M1TLbXNCVkeHUh?=
JVM-3 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WwXmlEPTB;MUiuO|E4KM7:TR?= M4jmNHNCVkeHUh?=
RL NFjQ[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\3TWM2OD1{MD6zPFgh|ryP M1fOXnNCVkeHUh?=
EC-GI-10 M2XBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJzLkKwOFEh|ryP M1Oy[HNCVkeHUh?=
LNCaP-Clone-FGC M4DHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jVWGlEPTB;MkGuOlc3QCEQvF2= MkDpV2FPT0WU
IMR-5 NFOyPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSzUFV{UUN3ME2yNU45PDl2IN88US=> M32x[XNCVkeHUh?=
KP-N-YS M2i4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJzLki3OUDPxE1? NW\OTmVtW0GQR1XS
Mo-T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\GNpdKSzVyPUKyMlIyQDVizszN MXHTRW5ITVJ?
NCI-H128 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv6TWM2OD1{Mz61PFU{KM7:TR?= MkCyV2FPT0WU
RH-1 NX\UN3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Ptb2lEPTB;MkOuO|g3PiEQvF2= MmjFV2FPT0WU
NCI-H2171 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ThOmlEPTB;MkSuNlQ5PSEQvF2= Ml\CV2FPT0WU
RPMI-8866 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor6TWM2OD1{Nj63OFIh|ryP M{XvS3NCVkeHUh?=
SK-N-FI Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vY[mlEPTB;MkeuN|gyOSEQvF2= MVLTRW5ITVJ?
LOXIMVI NX;VXFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITSZmVKSzVyPUK3MlgxPTFizszN NVvqSotHW0GQR1XS
P31-FUJ M{LrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPPTWM2OD1|MT61N|c1KM7:TR?= M2n1TXNCVkeHUh?=
KMS-12-PE M2jRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW4TWM2OD12OT61N|AzKM7:TR?= MojXV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ